New Bandage-Like matrix could speed healing after skin cancer removal
NCT ID NCT06578650
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a synthetic fiber matrix called Restrata, placed directly into surgical wounds after skin cancer removal. Researchers will track how long it takes for the wound bed to granulate (fill in with new tissue) and fully heal. The trial enrolls 34 adults with wounds between 4 and 36 square centimeters.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Synthetic electrospun fiber matrix (Restrata)
- What this could lead to
- If it works, this could provide a faster, more effective way to heal wounds after skin cancer surgery, reducing recovery time and complications.
- What could go wrong
- This is a small, early-stage trial with only 34 participants and no comparison group, so results may not apply to everyone. The device may not improve healing over standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 34 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2024
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients will be enrolled in a University Hospital Setting
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patient is at least 18 years old 2. Patient plans to undergo surgical resection of a cutaneous neoplasm 3. Patient is willing and capable of complying with all protocol requirements 4. Patient or legally authorized representative (LAR) is willing to provide written informed consent prior to participation in study 5. Post-resection surgical wound with a surface area of ≥4 cm2 and ≤ 36cm2 Exclusion Criteria: 1. Inability to give informed consent or to complete the procedures required for study completion 2. Patient has been previously enrolled into this study, or is currently participating in another drug or device study that has not reached its primary endpoint 3. Patient is pregnant, breast feeding or planning to become pregnant 4. Patient has a known allergy to resorbable suture materials, e.g. Polyglactin 910 (PGLA), Polydioxanone (PDS) 5. Patients receiving any immunotherapy, radiation, or chemotherapy within the past four weeks prior to resection surgery. 6. Patient has a life expectancy less than six months as assessed by the investigator 7. Patient has an additional non-study related wound within 3 cm of the study wound 8. Study wound is located on the hands or feet 9. Patient has been diagnosed with osteomalacia 10. Resection defect from a squamous cell carcinoma arising from a chronic wound 11. Patient has an uncontrolled thyroid disorder 12. Hgb A1c \> 12% within 3 months prior to enrollment in patients with a known history of diabetes 13. Patient has a BMI \> 34.9 14. Patient has used any tobacco product within the past 30 days prior to surgery 15. Patients with chronic kidney disease on peritoneal or hemodialysis, or with an estimated glomerular filtration rate less than 15mL/min 16. Patients with severe liver disease with active cirrhosis defined as a gross ascites upon clinical exam or a Model for End-stage Liver Disease (MELD)-Na score greater than 15 17. Patient not in reasonable metabolic control in the judgement of the investigator 18. Patient has a known history of poor compliance with medical treatment 19. Patient has a history of radiotherapy to wound bed of interest 20. Patient has been diagnosed with at least one of the following autoimmune connective tissue diseases: lupus, vasculitis, sickle cell, or uncontrolled rheumatoid arthritis 21. Active infection, undrained abscess, or critical colonization of the wound with bacteria in the judgement of the investigator
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Malignant cutaneous neoplasm are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Nevada - Las Vegas
RECRUITINGLas Vegas, Nevada, 89102, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple ointment make surgical scars heal better?
- Can a dissolvable dressing get burn patients to skin grafts faster?
- Can glue and barbed sutures beat staples for joint surgery wounds?
- Eye drop gel shows promise for skin graft healing, but trial stalls
- Stitch showdown: which wound closure method wins for emergency belly surgery?
- New wound scanner aims to spot hidden bacteria